NASDAQ:SGEN Seagen (SGEN) Stock Forecast, Price & News $213.70 +7.31 (+3.54%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$213.20▼$214.0050-Day Range$191.57▼$213.7052-Week Range$116.08▼$214.00Volume3.16 million shsAverage Volume1.42 million shsMarket Capitalization$40.11 billionP/E RatioN/ADividend YieldN/APrice Target$190.47 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Seagen MarketRank™ ForecastAnalyst RatingHold2.35 Rating ScoreUpside/Downside10.9% Downside$190.47 Price TargetShort InterestBearish3.57% of Shares Sold ShortDividend StrengthN/ASustainability-2.62Upright™ Environmental ScoreNews Sentiment0.63Based on 16 Articles This WeekInsider TradingSelling Shares$4.91 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.40) to ($1.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.66 out of 5 starsMedical Sector845th out of 963 stocksBiological Products, Except Diagnostic Industry132nd out of 158 stocks 1.2 Analyst's Opinion Consensus RatingSeagen has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 6 buy ratings, 11 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $190.47, Seagen has a forecasted downside of 10.9% from its current price of $213.70.Amount of Analyst CoverageSeagen has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.57% of the outstanding shares of Seagen have been sold short.Short Interest Ratio / Days to CoverSeagen has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Seagen has recently increased by 8.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSeagen does not currently pay a dividend.Dividend GrowthSeagen does not have a long track record of dividend growth. Previous Next 1.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeagen has received a -3.11% net impact score from Upright. The largest negative impact of Seattle Genetics in category "Physical diseases" seems to be driven mostly by its "Brentuximab vedotin", "Enfortumab vedotin", and "Tucatinib" products. See details.Environmental SustainabilityThe Environmental Impact score for Seagen is -2.62. Previous Next 3.7 News and Social Media Coverage News SentimentSeagen has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Seagen this week, compared to 5 articles on an average week.Search Interest6 people have searched for SGEN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows8 people have added Seagen to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,912,749.00 in company stock.Percentage Held by Insiders25.90% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.26% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seagen are expected to grow in the coming year, from ($3.40) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seagen is -54.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seagen is -54.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeagen has a P/B Ratio of 14.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Seagen (NASDAQ:SGEN) StockSeagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.Read More SGEN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGEN Stock News HeadlinesSeptember 22, 2023 | marketbeat.comSeagen, Activision Blizzard rise; Scholastic, Natural Alternatives fall, Friday, 9/22/2023Stocks that are trading heavily or have substantial price changes on Friday: Seagen, Activision Blizzard rise; Scholastic, Natural Alternatives fallSeptember 20, 2023 | marketbeat.comFlee to Healthcare Stocks if Recession Rears its Head? (SGEN)In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.September 24, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.September 24, 2023 | americanbankingnews.comSeagen (NASDAQ:SGEN) Receives New Coverage from Analysts at StockNews.comSeptember 24, 2023 | americanbankingnews.comSeagen (NASDAQ:SGEN) Reaches New 1-Year High at $214.00September 22, 2023 | investing.comSeagen gains after 'unsuprising' trial resultSeptember 22, 2023 | msn.comWhy Is Seagen Stock Trading Higher Today?September 22, 2023 | markets.businessinsider.comSeagen, Astellas Pharma Report Positive Topline Results From EV-302 TrialSeptember 24, 2023 | Legacy Research (Ad)The Real Reason They Murdered JFK?Some people believe JFK was murdered because of his executive order 11110 that would have reduced the power of the Federal Reserve. Regardless if that’s true or not… The Fed is now involved in a new controversy that could have drastic consequences for the US dollar.September 22, 2023 | markets.businessinsider.comSeagen Up In Pre-Market After Positive Results From EV-302 TrialSeptember 18, 2023 | americanbankingnews.comSeagen Inc. (NASDAQ:SGEN) Receives Average Rating of "Hold" from AnalystsSeptember 16, 2023 | americanbankingnews.comSeagen (NASDAQ:SGEN) Coverage Initiated by Analysts at StockNews.comSeptember 12, 2023 | benzinga.com$1000 Invested In This Stock 15 Years Ago Would Be Worth $16,000 TodaySeptember 11, 2023 | msn.comNurix (NRIX) Stock Increases 9% in a Month: Here's WhySeptember 8, 2023 | markets.businessinsider.comSeagen (SGEN) Gets a Hold from BTIGSeptember 6, 2023 | businesswire.comGenmab and Seagen Announce That TIVDAK ® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical ...August 31, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Seagen (SGEN) and Gain Therapeutics (GANX)August 25, 2023 | benzinga.comHere's How Much You Would Have Made Owning Seagen Stock In The Last 10 YearsAugust 16, 2023 | msn.comSeagen's Positive Trial Outcomes: Analyst Says The Update Might Double Tukysa's Current MarketAugust 16, 2023 | reuters.comSeagen's breast cancer therapy meets main goal in late-stage studyAugust 16, 2023 | finance.yahoo.comSeagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast CancerAugust 10, 2023 | benzinga.comIf You Invested $100 In This Stock 15 Years Ago, You Would Have $1,600 TodayAugust 6, 2023 | msn.com2023 shaping up to be biggest year for biopharma M&A since pandemicAugust 4, 2023 | msn.comMorgan Stanley Reiterates Seagen (SGEN) Equal-Weight RecommendationAugust 4, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Seagen (SGEN) and Prothena (PRTA)August 3, 2023 | finance.yahoo.comSeagen Inc.: Seagen Earnings: Robust Product Sales and Pipeline Advances; Acquisition by Pfizer on TrackAugust 2, 2023 | finance.yahoo.comSeattle Genetics (SGEN) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesSee More Headlines Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Email Address SGEN Company Calendar Last Earnings8/02/2023Today9/24/2023Next Earnings (Estimated)10/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGEN CUSIP81257810 CIK1060736 Webwww.seattlegenetics.com Phone(425) 527-4000Fax425-527-4001Employees3,256Year Founded1998Price Target and Rating Average Stock Price Forecast$190.47 High Stock Price Forecast$229.00 Low Stock Price Forecast$129.00 Forecasted Upside/Downside-10.9%Consensus RatingHold Rating Score (0-4)2.35 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($3.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-610,310,000.00 Net Margins-33.54% Pretax Margin-32.89% Return on Equity-26.46% Return on Assets-20.24% Debt Debt-to-Equity RatioN/A Current Ratio3.30 Quick Ratio2.66 Sales & Book Value Annual Sales$1.96 billion Price / Sales20.44 Cash FlowN/A Price / Cash FlowN/A Book Value$15.10 per share Price / Book14.15Miscellaneous Outstanding Shares187,700,000Free Float139,084,000Market Cap$40.11 billion OptionableOptionable Beta0.48 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. David R. Epstein B.Sc. (Age 61)M.B.A., CEO & Director Comp: $1.39MMr. Todd E. Simpson (Age 62)Chief Financial Officer Comp: $1.26MDr. Vaughn B. Himes Ph.D. (Age 62)Chief Technical Officer Comp: $1.08MMs. Jean I. Liu J.D. (Age 55)M.S., Chief Legal Officer & Corp. Sec. Comp: $1.23MMr. Charles R. Romp (Age 55)Exec. VP of Commercial U.S. Comp: $1.08MDr. Roger D. Dansey M.D. (Age 67)Chief Medical Officer and Pres of R&D Comp: $2.48MMr. William ComptonSr. VP of Global Information Technology & CIOMr. David CaouetteVP of Corp. CommunicationsMr. Matt SkeltonVP of MarketingMs. Peggy M. PinkstonChief HR OfficerMore ExecutivesKey CompetitorsBiogenNASDAQ:BIIBNeurocrine BiosciencesNASDAQ:NBIXGilead SciencesNASDAQ:GILDAmgenNASDAQ:AMGNModernaNASDAQ:MRNAView All CompetitorsInsiders & InstitutionsRoger D DanseySold 71 sharesTotal: $14,661.50 ($206.50/share)Charles R RompSold 45 sharesTotal: $9,292.50 ($206.50/share)Vaughn B HimesSold 80 sharesTotal: $16,520.00 ($206.50/share)Baystate Wealth Management LLCBought 3,265 shares on 9/21/2023Ownership: 0.002%Bluefin Capital Management LLCBought 2,656,100 shares on 9/11/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SGEN Stock - Frequently Asked Questions Should I buy or sell Seagen stock right now? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares. View SGEN analyst ratings or view top-rated stocks. What is Seagen's stock price forecast for 2023? 17 analysts have issued 12 month price targets for Seagen's stock. Their SGEN share price forecasts range from $129.00 to $229.00. On average, they predict the company's stock price to reach $190.47 in the next year. This suggests that the stock has a possible downside of 10.9%. View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts. How have SGEN shares performed in 2023? Seagen's stock was trading at $128.51 at the start of the year. Since then, SGEN shares have increased by 66.3% and is now trading at $213.70. View the best growth stocks for 2023 here. When is Seagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. View our SGEN earnings forecast. How were Seagen's earnings last quarter? Seagen Inc. (NASDAQ:SGEN) issued its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($1.13) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by $0.35. The biotechnology company had revenue of $603.83 million for the quarter, compared to analyst estimates of $555.68 million. Seagen had a negative net margin of 33.54% and a negative trailing twelve-month return on equity of 26.46%. What ETFs hold Seagen's stock? ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), AltShares Event-Driven ET (EVNT), Principal Healthcare Innovators ETF (BTEC) and AltShares Merger Arbitrage ETF (ARB). What is Clay B. Siegall's approval rating as Seagen's CEO? 107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Seagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA). What is Seagen's stock symbol? Seagen trades on the NASDAQ under the ticker symbol "SGEN." Who are Seagen's major shareholders? Seagen's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.42%), Capital World Investors (4.84%), Capital International Investors (3.42%), State Street Corp (1.78%), Bluefin Capital Management LLC (0.00%) and Bluefin Capital Management LLC (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes. View institutional ownership trends. How do I buy shares of Seagen? Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Seagen's stock price today? One share of SGEN stock can currently be purchased for approximately $213.70. How much money does Seagen make? Seagen (NASDAQ:SGEN) has a market capitalization of $40.11 billion and generates $1.96 billion in revenue each year. The biotechnology company earns $-610,310,000.00 in net income (profit) each year or ($3.89) on an earnings per share basis. How many employees does Seagen have? The company employs 3,256 workers across the globe. Does Seagen have any subsidiaries? The following companies are subsidiares of Seagen: Cascadian Therapeutics.Read More How can I contact Seagen? Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001. This page (NASDAQ:SGEN) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.